Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.065 SEK | +8.67% | +12.34% | -76.64% |
28/03 | Elicera Therapeutics AB Announces Director Changes | CI |
06/03 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.74Cr 34.89L 29Cr |
---|---|---|---|---|---|
Net income 2024 * | -4.8Cr -44.8L -37Cr | Net income 2025 * | -3.4Cr -31.74L -26Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | 3.5Cr 32.67L 27Cr | Net cash position 2025 * | 4.1Cr 38.27L 32Cr | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.44
x | P/E ratio 2025 * |
-0.63
x | Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 38.42% |
1 day | +8.67% | ||
1 week | +12.34% | ||
Current month | +13.30% | ||
1 month | -10.88% | ||
3 months | -38.26% | ||
6 months | -78.27% | ||
Current year | -76.64% |
Managers | Title | Age | Since |
---|---|---|---|
Magnus Essand
FOU | Founder | 60 | 01/14/01 |
Di Yu
FOU | Founder | 39 | 01/14/01 |
Jamal El-Mosleh
CEO | Chief Executive Officer | 43 | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 01/20/01 | |
Director/Board Member | 73 | 01/20/01 | |
Chairman | 68 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
17/24/17 | 1.065 | +8.67% | 609,025 |
16/24/16 | 0.98 | +15.02% | 746,476 |
15/24/15 | 0.852 | -5.12% | 81,514 |
14/24/14 | 0.898 | -0.88% | 112,062 |
13/24/13 | 0.906 | -3.62% | 59,257 |
Delayed Quote Nasdaq Stockholm, May 17, 2024 at 08:59 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.64% | 32.14L | |
+32.09% | 69TCr | |
+29.39% | 59TCr | |
-1.34% | 37TCr | |
+20.34% | 33TCr | |
+7.39% | 29TCr | |
+14.25% | 24TCr | |
-3.03% | 21TCr | |
+10.02% | 21TCr | |
+8.49% | 17TCr |
- Stock Market
- Equities
- ELIC Stock